Immunovia applies to AMA for PLA code

2020 02 14 01 40 9390 Cancer Pancreatic 400

Immunovia recently submitted an application for a current procedural terminology (CPT) proprietary laboratory analyses (PLA) code to the American Medical Association (AMA) for the company's IMMray PanCan-d test.

The company has touted the results of a study showing that the test detected stage I/II pancreatic ductal adenocarcinoma with 99% specificity and 89% sensitivity.

The company said a PLA code would allow healthcare professionals to identify the IMMray PanCan-d test when submitting information and claims to health insurances and payers. If approved, the issued PLA code would be published on July 1 and become effective on October 1.

The CPT codes give doctors and healthcare professionals a uniform language for coding medical services and procedures.

Page 1 of 1